diisopropyl phosphorocyanidate | 28616-50-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: diisopropyl phosphorocyanidate
• 英文别名: Di(propan-2-yloxy)phosphorylformonitrile
• CAS: 28616-50-4
• 化学式: C₇H₁₄NO₃P
• 分子量: 191.167
• InChiKey: YAOQCOUSDPCULI-UHFFFAOYSA-N

物化性质

• 沸点：
  53-55 °C(Press: 0.2 Torr)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diisopropyl phosphorocyanidate 、 C.I.酸性橙108 以 氯仿 为溶剂， 生成 Phosphorsaeure-<(2-amino-aethyl)-diisopropylester>
  参考文献：
  名称：

  Effect of the structure of phosphylating agents on their reaction with ethanolamine, an ambident nucleophile

  摘要：

  一系列磷酰化试剂（RR′P(O)X）与乙醇胺的反应已经被研究，确定了来自亲核氨基和羟基的产物的相对产率。一般来说，当R和R′从二甲胺基经过烷氧基变化到甲基时，O-磷酰化的量会增加，当离去基团（X）从OP(O)RR′变化为CN时也会增加。唯一的例外是当R为二甲胺基且X为Cl时。当X为F时，只观察到O-磷酰化。因此，发现了一系列基本连续变化的选择性。结果讨论了在形成过渡态时涉及的电荷转移量，该量被认为由亲电试剂决定。当电荷转移量较小时，诸如溶剂化和亲核试剂的电离势等因素对激活能的贡献最为重要，导致N-磷酰化。随着电荷转移量的增加，键合能量成为主导因素，O-磷酰化更为优先。

  DOI：

  10.1139/v70-223
• 作为产物：
  描述：

  氢氰酸 、 氯磷酸二异丙酯 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 0.25h， 以88%的产率得到diisopropyl phosphorocyanidate
  参考文献：
  名称：

  An Efficient Synthesis of Dialkyl Phosphorocyanidates

  摘要：

  Dialkyl phosphorocyanidates 2a-2g were prepared in high yield from dialkyl phosphorochloridates and hydrogen cyanide in the presence of triethylamine in ether The white precipitates formed in the reaction of diethyl phosphorochlorodates and triethylamine were verified as triethylammonium chloride, not the similar phosphoryltriethylammonium chloride by FAB-MS, ESI-MS, P-31-NMR, and H-1-NMR.

  DOI：

  10.1080/104265090917673

文献信息

• Imidazopyridine compounds as 5-HT4 receptor modulators
  申请人：——

  公开号：US20030092699A1

  公开（公告）日：2003-05-15

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein R 1 is hydrogen, halo or alkyl; R 2 and R 3 are independently hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl or hydroxyalkyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached may form hetrocyclic; R 4 is hydrogen, halo, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R 5 is hydrogen, halo, alkyl, alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R 6 is hydrogen, alkyl or alkoxyalkyl; X is NR 9 wherein R 9 is hydrogen or alkyl; and Y is (CR 7 R 8 ) n wherein n is an integer from 0 to 5. These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了式(I)的化合物： 1 或其药学上可接受的盐，其中R 1 为氢、卤素或烷基；R 2 和R 3 独立地为氢、烷基、烯基、炔基、氨基烷基或羟基烷基；或R 2 和R 3 与它们连接的氮原子一起可能形成杂环；R 4 为氢、卤素、酰基、氨基、酰胺基、芳基、芳基烷基或杂芳基；R 5 为氢、卤素、烷基、烯基、炔基、酰基、氨基、酰胺基、芳基、芳基烷基或杂芳基；R 6 为氢、烷基或烷氧基烷基；X为NR 9 ，其中R 9 为氢或烷基；Y为(CR 7 R 8 ) n ，其中n为0至5的整数。 这些化合物具有5-HT 4 受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征或类似疾病的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。
• Synthesis of Phosphorocyanidates via Phosphorochloridates
  作者：Enxue Shi、Chengxin Pei

  DOI：10.1080/10426500307856

  日期：2003.5.1

  Dialkyl phosphorocyanidates ( 2 ) were obtained from dialkyl phosphorochloridates ( 1 ) in high yield (80-86%) at room temperature in methyl cyanide. Reaction between diethyl phosphorochloridate and potassium cyanide was greatly influenced by the solvents used. Tetraethyl pyrophosphate also was found to react with potassium cyanide to give diethyl phosphorocyanidate in methyl cyanide.

  在室温下在甲基氰化物中以高产率（80-86%）从二烷基磷酰氯（1）获得二烷基磷氰（2）。所用溶剂极大地影响了二乙基氯化磷和氰化钾之间的反应。还发现焦磷酸四乙酯与氰化钾反应，在甲基氰化物中得到磷酸二乙酯。
• [EN] N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES DE PIPERIDINYL-IMIDAZOPYRIDINE N-SUBSTITUES UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2004026868A1

  公开（公告）日：2004-04-01

  This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α are selected from the group consisting of aryl groups, hydroxy groups, oxo groups, etc.; said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, etc.; or a pharmaceutically acceptable amide of such compound, or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中R1代表氢原子或卤原子；R2代表氢原子，等等；R3代表具有1至10个碳原子的烷基基团；R3中的烷基基团被来自α取代基组的至少一个取代基所取代；所述α取代基选自芳基、羟基、酮基等组成的组；所述芳基含有6至10个碳原子；所述芳基未取代或被具有1至6个碳原子的至少一个烷基基团所取代；所述杂环基团和杂环基团中的杂环基在杂环羰基中是含有1至4个来自氮原子等组成的杂原子的5至10元环基团；或者是该化合物的药学上可接受的酰胺，或者是该化合物的药学上可接受的酯，以及其药学上可接受的盐。这些化合物具有5-HT4受体结合活性，因此对于哺乳动物，特别是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等的治疗是有用的。该发明还提供了包含上述化合物的药物组合物。
• [EN] SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS<br/>[FR] COMPOSES METHYLARYL- OU HETEROARYLAMIDES SUBSTITUES
  申请人：PFIZER JAPAN INC

  公开号：WO2005105732A1

  公开（公告）日：2005-11-10

  This invention provides a compound of the formula (I), wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种化合物，其化学式为（I），其中X代表碳原子或类似物：Y代表亚胺基或类似物：R1代表具有1至6个碳原子的烷基基团或类似物：R2和R3独立地代表氢原子或类似物。这些化合物对于治疗由前列腺素介导的疾病状况，如哺乳动物中的疼痛等，具有用处。本发明还提供了包括上述化合物的药物组合物。
• Bicyclic compounds as NR2B receptor antagonists
  申请人：——

  公开号：US20040204409A1

  公开（公告）日：2004-10-14

  This invention provides a compound of the formula (I): 1 wherein R 1 and R 2 independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like: These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物，其化学式为(I):其中R1和R2分别表示氢原子或类似物；X表示共价键或类似物；A表示具有8至12个环原子的双环、芳香、饱和或部分不饱和的杂环或碳环基团；或类似物；B表示具有5至6个环原子的苯基或杂环基团；或类似物。这些化合物对于治疗由NMDA NR2B受体过度活化引起的疾病情况，如疼痛等在哺乳动物中具有用途。这项发明还提供了包含上述化合物的药物组合物。